AlphaStocks
5.4
Consider Buy

Protagonist Therapeutics, Inc (PTGX)

As of Sep 19, 2026, Protagonist Therapeutics, Inc (PTGX) scores 5.4/10 on AlphaStocks' five-model composite, #81 of 168 Health Care stocks.

Health Care / Biotechnology

S&P SmallCap 600

$142.93

Below average on several measures. Research carefully.

Consider Buy

Score based on 2 of 5 models — limited data

Data as of Sep 19, 2026

#81out of 168 in Health Care

Is Protagonist Therapeutics, Inc a Good Investment in 2026?

Protagonist Therapeutics, Inc (PTGX) scores 5.4 out of 10 on AlphaStocks' composite model, earning a Consider Buy rating. The Piotroski model is the most favorable, rating Protagonist Therapeutics, Inc as Neutral. However, the Graham model rates it Caution. Protagonist Therapeutics, Inc ranks #81 out of 168 stocks in the Health Care sector.

This summary is algorithmically generated and is not financial advice.

Key Metrics

ROE-12.1Market Cap10B

Valuation

Currently unprofitable — fair value estimate not available.

Fair value estimate not available for this stock.

5-Model Analysis

Each model evaluates this stock from a different angle. Combined, they form the composite score above.

Piotroski

Neutral

4/9

Buffett

Limited Data

Business quality & competitive moat

Graham

Caution

Price vs intrinsic value

Lynch

Limited Data

Growth rate vs price (PEG)

Greenblatt

Limited Data

Earnings yield + return on capital

Frequently Asked Questions

Is Protagonist Therapeutics, Inc (PTGX) a good investment?
As of Sep 19, 2026, Protagonist Therapeutics, Inc (PTGX) scores 5.4/10 on AlphaStocks' five-model composite, #81 of 168 Health Care stocks. That score is below average, suggesting caution. Currently unprofitable — fair value estimate not available.
What is Protagonist Therapeutics, Inc's Piotroski F-Score?
Protagonist Therapeutics, Inc's Piotroski F-Score status is Neutral. The raw score is 4/9. The Piotroski F-Score evaluates financial health using 9 fundamental signals including profitability, leverage, and operating efficiency.
Is PTGX overvalued or undervalued?
A precise fair value estimate is not available for PTGX. Currently unprofitable — fair value estimate not available.
How does PTGX compare to other Health Care stocks?
Protagonist Therapeutics, Inc ranks #81 out of 168 stocks in the Health Care sector, placing it in the top 48% of its sector by composite score. This is an above-average position relative to sector peers.
What do investment models say about PTGX?
AlphaStocks evaluates PTGX using five proven investment models. Piotroski: Neutral; Graham: Caution. These models are combined into a single composite score of 5.4/10.

Similar Stocks

ABBVINCYHRMY

Compare PTGX with

ABBV vs PTGXINCY vs PTGXHRMY vs PTGXAZN vs PTGX

Scores are algorithm-generated research tools, not investment recommendations. Past performance does not guarantee future results. Always do your own due diligence. Full disclaimer